Results at 2 Years after Gene Therapy for RPE65-Deficient Leber Congenital Amaurosis and Severe Early-Childhood-Onset Retinal Dystrophy

Richard Weleber, Mark Pennesi, David Wilson, Shalesh Kaushal, Laura Erker, Lauren Jensen, Maureen T. McBride, Terence R. Flotte, Margaret Humphries, Roberto Calcedo, William W. Hauswirth, Jeffrey D. Chulay, J. Timothy Stout

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Purpose: To provide an initial assessment of the safety of a recombinant adeno-associated virus vector expressing RPE65 (rAAV2-CB-hRPE65) in adults and children with retinal degeneration caused by RPE65 mutations. Design: Nonrandomized, multicenter clinical trial. Participants: Eight adults and 4 children, 6 to 39 years of age, with Leber congenital amaurosis (LCA) or severe early-childhood-onset retinal degeneration (SECORD). Methods: Patients received a subretinal injection of rAAV2-CB-hRPE65 in the poorer-seeing eye, at either of 2 dose levels, and were followed up for 2 years after treatment. Main Outcome Measures: The primary safety measures were ocular and nonocular adverse events. Exploratory efficacy measures included changes in best-corrected visual acuity (BCVA), static perimetry central 30° visual field hill of vision (V30) and total visual field hill of vision (VTOT), kinetic perimetry visual field area, and responses to a quality-of-life questionnaire. Results: All patients tolerated subretinal injections and there were no treatment-related serious adverse events. Common adverse events were those associated with the surgical procedure and included subconjunctival hemorrhage in 8 patients and ocular hyperemia in 5 patients. In the treated eye, BCVA increased in 5 patients, V30 increased in 6 patients, VTOT increased in 5 patients, and kinetic visual field area improved in 3 patients. One subject showed a decrease in BCVA and 2 patients showed a decrease in kinetic visual field area. Conclusions: Treatment with rAAV2-CB-hRPE65 was not associated with serious adverse events, and improvement in 1 or more measures of visual function was observed in 9 of 12 patients. The greatest improvements in visual acuity were observed in younger patients with better baseline visual acuity. Evaluation of more patients and a longer duration of follow-up will be needed to determine the rate of uncommon or rare side effects or safety concerns.

Original languageEnglish (US)
JournalOphthalmology
DOIs
StateAccepted/In press - Nov 25 2015

Fingerprint

Leber Congenital Amaurosis
Genetic Therapy
Visual Fields
Visual Acuity
Retinal Degeneration
Visual Field Tests
Safety
Early Onset Severe Retinal Dystrophy
Dependovirus
Injections
Hyperemia
Multicenter Studies

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Results at 2 Years after Gene Therapy for RPE65-Deficient Leber Congenital Amaurosis and Severe Early-Childhood-Onset Retinal Dystrophy. / Weleber, Richard; Pennesi, Mark; Wilson, David; Kaushal, Shalesh; Erker, Laura; Jensen, Lauren; McBride, Maureen T.; Flotte, Terence R.; Humphries, Margaret; Calcedo, Roberto; Hauswirth, William W.; Chulay, Jeffrey D.; Stout, J. Timothy.

In: Ophthalmology, 25.11.2015.

Research output: Contribution to journalArticle

Weleber, Richard ; Pennesi, Mark ; Wilson, David ; Kaushal, Shalesh ; Erker, Laura ; Jensen, Lauren ; McBride, Maureen T. ; Flotte, Terence R. ; Humphries, Margaret ; Calcedo, Roberto ; Hauswirth, William W. ; Chulay, Jeffrey D. ; Stout, J. Timothy. / Results at 2 Years after Gene Therapy for RPE65-Deficient Leber Congenital Amaurosis and Severe Early-Childhood-Onset Retinal Dystrophy. In: Ophthalmology. 2015.
@article{a8e831f162e54601a5fb20d0e9dd7b7f,
title = "Results at 2 Years after Gene Therapy for RPE65-Deficient Leber Congenital Amaurosis and Severe Early-Childhood-Onset Retinal Dystrophy",
abstract = "Purpose: To provide an initial assessment of the safety of a recombinant adeno-associated virus vector expressing RPE65 (rAAV2-CB-hRPE65) in adults and children with retinal degeneration caused by RPE65 mutations. Design: Nonrandomized, multicenter clinical trial. Participants: Eight adults and 4 children, 6 to 39 years of age, with Leber congenital amaurosis (LCA) or severe early-childhood-onset retinal degeneration (SECORD). Methods: Patients received a subretinal injection of rAAV2-CB-hRPE65 in the poorer-seeing eye, at either of 2 dose levels, and were followed up for 2 years after treatment. Main Outcome Measures: The primary safety measures were ocular and nonocular adverse events. Exploratory efficacy measures included changes in best-corrected visual acuity (BCVA), static perimetry central 30° visual field hill of vision (V30) and total visual field hill of vision (VTOT), kinetic perimetry visual field area, and responses to a quality-of-life questionnaire. Results: All patients tolerated subretinal injections and there were no treatment-related serious adverse events. Common adverse events were those associated with the surgical procedure and included subconjunctival hemorrhage in 8 patients and ocular hyperemia in 5 patients. In the treated eye, BCVA increased in 5 patients, V30 increased in 6 patients, VTOT increased in 5 patients, and kinetic visual field area improved in 3 patients. One subject showed a decrease in BCVA and 2 patients showed a decrease in kinetic visual field area. Conclusions: Treatment with rAAV2-CB-hRPE65 was not associated with serious adverse events, and improvement in 1 or more measures of visual function was observed in 9 of 12 patients. The greatest improvements in visual acuity were observed in younger patients with better baseline visual acuity. Evaluation of more patients and a longer duration of follow-up will be needed to determine the rate of uncommon or rare side effects or safety concerns.",
author = "Richard Weleber and Mark Pennesi and David Wilson and Shalesh Kaushal and Laura Erker and Lauren Jensen and McBride, {Maureen T.} and Flotte, {Terence R.} and Margaret Humphries and Roberto Calcedo and Hauswirth, {William W.} and Chulay, {Jeffrey D.} and Stout, {J. Timothy}",
year = "2015",
month = "11",
day = "25",
doi = "10.1016/j.ophtha.2016.03.003",
language = "English (US)",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Results at 2 Years after Gene Therapy for RPE65-Deficient Leber Congenital Amaurosis and Severe Early-Childhood-Onset Retinal Dystrophy

AU - Weleber, Richard

AU - Pennesi, Mark

AU - Wilson, David

AU - Kaushal, Shalesh

AU - Erker, Laura

AU - Jensen, Lauren

AU - McBride, Maureen T.

AU - Flotte, Terence R.

AU - Humphries, Margaret

AU - Calcedo, Roberto

AU - Hauswirth, William W.

AU - Chulay, Jeffrey D.

AU - Stout, J. Timothy

PY - 2015/11/25

Y1 - 2015/11/25

N2 - Purpose: To provide an initial assessment of the safety of a recombinant adeno-associated virus vector expressing RPE65 (rAAV2-CB-hRPE65) in adults and children with retinal degeneration caused by RPE65 mutations. Design: Nonrandomized, multicenter clinical trial. Participants: Eight adults and 4 children, 6 to 39 years of age, with Leber congenital amaurosis (LCA) or severe early-childhood-onset retinal degeneration (SECORD). Methods: Patients received a subretinal injection of rAAV2-CB-hRPE65 in the poorer-seeing eye, at either of 2 dose levels, and were followed up for 2 years after treatment. Main Outcome Measures: The primary safety measures were ocular and nonocular adverse events. Exploratory efficacy measures included changes in best-corrected visual acuity (BCVA), static perimetry central 30° visual field hill of vision (V30) and total visual field hill of vision (VTOT), kinetic perimetry visual field area, and responses to a quality-of-life questionnaire. Results: All patients tolerated subretinal injections and there were no treatment-related serious adverse events. Common adverse events were those associated with the surgical procedure and included subconjunctival hemorrhage in 8 patients and ocular hyperemia in 5 patients. In the treated eye, BCVA increased in 5 patients, V30 increased in 6 patients, VTOT increased in 5 patients, and kinetic visual field area improved in 3 patients. One subject showed a decrease in BCVA and 2 patients showed a decrease in kinetic visual field area. Conclusions: Treatment with rAAV2-CB-hRPE65 was not associated with serious adverse events, and improvement in 1 or more measures of visual function was observed in 9 of 12 patients. The greatest improvements in visual acuity were observed in younger patients with better baseline visual acuity. Evaluation of more patients and a longer duration of follow-up will be needed to determine the rate of uncommon or rare side effects or safety concerns.

AB - Purpose: To provide an initial assessment of the safety of a recombinant adeno-associated virus vector expressing RPE65 (rAAV2-CB-hRPE65) in adults and children with retinal degeneration caused by RPE65 mutations. Design: Nonrandomized, multicenter clinical trial. Participants: Eight adults and 4 children, 6 to 39 years of age, with Leber congenital amaurosis (LCA) or severe early-childhood-onset retinal degeneration (SECORD). Methods: Patients received a subretinal injection of rAAV2-CB-hRPE65 in the poorer-seeing eye, at either of 2 dose levels, and were followed up for 2 years after treatment. Main Outcome Measures: The primary safety measures were ocular and nonocular adverse events. Exploratory efficacy measures included changes in best-corrected visual acuity (BCVA), static perimetry central 30° visual field hill of vision (V30) and total visual field hill of vision (VTOT), kinetic perimetry visual field area, and responses to a quality-of-life questionnaire. Results: All patients tolerated subretinal injections and there were no treatment-related serious adverse events. Common adverse events were those associated with the surgical procedure and included subconjunctival hemorrhage in 8 patients and ocular hyperemia in 5 patients. In the treated eye, BCVA increased in 5 patients, V30 increased in 6 patients, VTOT increased in 5 patients, and kinetic visual field area improved in 3 patients. One subject showed a decrease in BCVA and 2 patients showed a decrease in kinetic visual field area. Conclusions: Treatment with rAAV2-CB-hRPE65 was not associated with serious adverse events, and improvement in 1 or more measures of visual function was observed in 9 of 12 patients. The greatest improvements in visual acuity were observed in younger patients with better baseline visual acuity. Evaluation of more patients and a longer duration of follow-up will be needed to determine the rate of uncommon or rare side effects or safety concerns.

UR - http://www.scopus.com/inward/record.url?scp=84963812408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963812408&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2016.03.003

DO - 10.1016/j.ophtha.2016.03.003

M3 - Article

C2 - 27102010

AN - SCOPUS:84963812408

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

ER -